<DOC>
	<DOCNO>NCT00158093</DOCNO>
	<brief_summary>Nebivolol one class drug know beta-blockers . These drug useful treatment high blood pressure , angina , abnormal heart rhythm follow heart attack . The purpose study explore potential nebivolol cause certain type abnormal heart rhythm , know QTc prolongation . The potential nebivolol cause adverse event compare three drug : atenolol , beta-blocker approve FDA ; Avelox ( moxifloxacin ) , anti-biotic approve use FDA know cause QTc prolongation ; placebo , drug look-alike contains drug . The work hypothesis 20 40 mg nebivolol would prolong correct QT interval measure peak nebivolol concentration ( i.e. , 2 hour dose ) Day 7 .</brief_summary>
	<brief_title>A Safety Evaluation ECG Intervals Blood Pressure Normal Healthy Volunteers After Use Nebivolol , Atenolol , Moxifloxacin , Placebo</brief_title>
	<detailed_description />
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Men nonpregnant , nonlactating woman 18 year old . Women declare postmenopausal surgical sterility . Women childbearing potential negative serum HCG within 2 week dose . Male subject weigh least 60 kg ( 132 lb ) , female subject weigh least 48 kg ( 106 lb ) . All volunteer weigh within 15 % ideal body weight ( IBW ) . Institutionalized Reported known do following : Used tobacco product . Ingested alcoholic , caffeine xanthine contain food beverage within 48 hour prior initial dose study medication Consumed grapefruit grapefruit containing product within 7 day prior initial dose study medication . Ingested vitamin herbal product within 48 hour prior initial dose study medication . Recently change dietary exercise habit significantly Used medication ( include overthecounter [ OTC ] ) within 14 day prior initial dose study medication . Used medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . Received investigational drug within 30 day prior initial dose study medication . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . History drug and/or alcohol abuse within 1 year prior study . Acute illness time either pre study medical evaluation dosing . Any laboratory result deem clinically significant physician . Abnormal clinically relevant ECG tracing . Donated lose significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . Allergic hypersensitive nebivolol , atenolol , Î² block drug moxifloxacin quinolone antibiotic . History seizures cerebrovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>